Showing results (21-30 of 1,186) with videos related to
Sort By:
Pageof 119
Pharmaceutical Statistics|July 17, 2019
Reference-based sensitivity analysis for time-to-event dataAndrew Atkinson, Michael G Kenward, Tim Clayton, et al.Pharmaceutical Statistics|September 4, 2014
The shrinking or disappearing observed treatment effectChristy Chuang-Stein, Simon KirbyPharmaceutical Statistics|October 6, 2015
Model free audit methodology for bias evaluation of tumour progression in oncologyAndrew Stone, Euan Macpherson, Ann Smith, et al.Pharmaceutical Statistics|November 13, 2015
Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecyDennis W Lendrem, B Clare Lendrem, Ruth Rowland-Jones, et al.Pharmaceutical Statistics|November 12, 2013
Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirementsRuud Boessen, Frederieke van der Baan, Rolf Groenwold, et al.Pharmaceutical Statistics|March 28, 2012
Comments on 'Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design' by Satoshi Morita and Junichi Sakamoto. Pharmaceutical StatisticsMd Monir Hossain, Zhongxue ChenPharmaceutical Statistics|June 7, 2016
A modified varying-stage adaptive phase II/III clinical trial designGaohong Dong, Marc VandemeulebroeckePharmaceutical Statistics|November 26, 2015
Practical guide to sample size calculations: non-inferiority and equivalence trialsLaura Flight, Steven A JuliousPharmaceutical Statistics|September 30, 2016
Estimating the reliability of repeatedly measured endpoints based on linear mixed-effects models. A tutorialWim Van der Elst, Geert Molenberghs, Ralf-Dieter Hilgers, et al.Pharmaceutical Statistics|September 12, 2019
A two-stage phase II clinical trial design with nested criteria for early stopping and efficacyMichelle DeVeaux, Michael Kane, Wei Wei, et al.Pageof 119